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This introductory article has been written in the form of a conversation between Pier Paolo
Pandolfi, Director of the Cancer Center of Beth Israel Deaconess Medical Center in Boston,
and Rosa Bernardi, a former post-doctoral fellow in the laboratory of Dr. Pandolfi, now prin-
cipal investigator at San Raffaele Scientific Institute in Milan, Italy. We have chosen this
atypical review format because we want to offer to our readers a more direct and personal
perspective on the first 20 years of research over the promyelocytic leukemia gene. This
article begins as an interview, but soon transforms into a dialog where we exchange our
thoughts on a number of issues around the past, present, and future research over the
biology of PML. We were particularly keen on emphasizing the aspects that we find most
interesting or challenging, therefore, we warn our readers that this will not be a compre-
hensive essay but rather a very personal view of what has been, is, and will be exciting
and interesting in the PML world, in our opinion.
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INTRODUCTION
The promyelocytic leukemia gene, PML was originally discovered
because of its involvement in acute promyelocytic leukemia (APL)
(1–4), and was later shown to encode a homo-multimeric protein
with predominant nuclear localization, wide tissue expression, and
prevalent tumor suppressive functions, both in hematological and
solid malignancies (Figure 1).
Twenty years of intense research activity carried out by a
number of laboratories and prompted by the generation of Pml
knock-out (KO) mice (5), have led to the description of PML
as a widely multifaceted protein that regulates many aspects of
normal physiology and pathology (Figure 1). Complexity is the
term that best defines PML at many levels: the PML gene under-
goes multiple alternative splicing processes and generates a variety
of PML mRNA species and protein isoforms; PML isoforms dif-
fer in a number of features, from protein interaction capabilities
and sub-cellular localization to specific functions within the cell;
PML functions are often subtle, and unveiled only upon specific
experimental challenges; the biochemistry of PML interactions is
particularly difficult to tackle because of the insolubility of PML
protein complexes. Regardless of these difficulties, or perhaps pre-
cisely because of them, the study of PML functions has constantly
attracted the attention of many researchers. Such keen interest
had led over the years to the incessant addition of new levels of
complexity to the biology of PML. Reconciling everything that is
currently known into a unifying working model is at the present
time impossible, and probably unnecessary. For this reason, we
have chosen to freely discuss about what we find most interest-
ing and promising about research on PML, beginning with a very
personal account on how it all started.
A DIALOG ON PML
Bernardi: Pier Paolo, in 1991 as a medical student to start with,
and a freshly graduated post-doctoral fellow in the laboratory of
Pier Giuseppe Pelicci (in those times leading his laboratory in
Perugia, now directing the Department of Experimental Oncol-
ogy at the European Institute of Oncology in Milan, Italy), you
cloned and characterized the PML transcript and its aberrant ver-
sion PML–RARα. This new genetic locus had been identified a
year earlier at the breakpoint of t (15;17) translocation along with
the retinoic acid receptor α gene (RARα) in APL through the work
of Letizia Longo and yourself in the Pelicci laboratory, as well as
by other groups (6–8). You told me once that cloning and char-
acterizing the PML gene was a tough race; one of those exciting
and hysterical moments in science when you know that like you
other people, in other laboratories, are working day and night to
publish their results first. Out of this race, within a time frame
of a few months, four papers described the characterization of
the PML gene [renamed PML after having been identified as Myl
(6)] and the PML–RARα fusion protein (1–4). This project must
have changed your life, and unquestionably shaped your career:
out of this line of research came your first KO mouse and your
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FIGURE 1 |Timeline of the milestone discoveries on PML.
longstanding interest for leukemia gene rearrangements, which
later widened to include a larger spectrum of projects on the
genetic bases of cancer. What do you recall of those early days?
What have been the most exciting or frustrating moments?
Pandolfi: In those times, I had just begun working in a labo-
ratory as a medical student and as a summer student after a few
years of thrilling philosophy studies at the University of Rome, and
everything about science and research was very novel and exciting.
Furthermore, the idea of cancer oncogenes really intrigued me.
The opportunity of being involved in such an ambitious project,
the cloning of a new cancer gene was from the get go pure adrena-
line. However, I will never forget when we obtained the first PML
mRNA sequence and attempted to find an open reading frame
that would mean something structurally: nothing! It was a big
disappointment. Now we know that PML has an RING domain
embedded into an RBCC or TRIM structure (9, 10), but at that
time RING fingers were not characterized. We were therefore really
in the dark. But the first antibody raised to recognize PML gave
the whole APL field some hope. We were seeing nuclear dots, what
we now call in jargon the PML-nuclear bodies [PML-NBs; Ref.
(11)]. This was indeed intriguing. But the real question that was
not making me sleep at night was whether PML was an onco-
gene, or else, and whether it would be important in the control of
hemopoiesis.
Bernardi: On my side, what I found most remarkable when I
begun working on PML is the beauty of its sub-cellular localization
into the PML-NBs. These distinctive macromolecular structures
had been known to exist since the 60s (12), but only in 1993 they
were identified as sites of accumulation of PML, being renamed
at that point PML-nuclear bodies (13). We now know a lot of
things about PML-NBs: they are donut-shaped, with a diameter
of 0.2–1.0µm, there is an average of 5–15 of them per cell nucleus,
and they are formed by a ring of proteins surrounding an empty
space [sometimes occupied by microgranular material proposed
to be ribonucleoproteins (12), with DNA and RNA localizing at the
periphery of the ring (14, 15)]. However, it seems to me that even
though we have learnt a lot about their biochemistry and func-
tion, much still remain to be uncovered. For instance, although we
keep referring to them as PML-NBs, as if they were homogeneous
structures, in reality they probably are not: they vary in dynam-
ics, biochemistry, and structure in the different phases of the cell
cycle [with mitotic PML aggregates being so peculiar to have been
termed mitotic accumulations of PML protein, or MAPPs (16)],
in different cell types (i.e., embryonic stem cells versus cell lines),
and upon different types of cellular stresses, such as heat shock
or inhibition of transcription (12). However, besides a general
recognition that there may be different types of PML-NBs, a pre-
cise characterization of their specific structure and function is far
from being revealed.
I am also wondering whether a better characterization of PML
protein isoforms may help us to better characterize different types
of PML-NBs. Indeed, one other striking feature of PML is the high
number of alternatively spliced mRNA molecules and protein iso-
forms that are generated from the PML gene. All PML isoforms
contain the N-terminal homo-multimerization domain [termed
RBCC or TRIM (9, 10)] that allows formation of high order mol-
ecular structures, but differ in their C-terminal regions (10), and
when expressed individually in Pml null cells form morphologi-
cally and dynamically different PML-NBs (17, 18). This suggests
that PML isoforms may play different roles in the formation and
maintenance of PML-NBs. However, in the absence of a compre-
hensive mapping of the relative expression of PML isoforms and
the relative composition of PML-NBs in different cell conditions,
the biological relevance of PML isoforms’ specificity and their reg-
ulation of PML-NBs still remains to be established. I think that
this is a very interesting field of research, where we should invest
more; especially considering that specific PML isoforms have been
suggested to have exclusive functions (19).
Pandolfi: Talking about PML isoforms and isoform specificity,
what has been overlooked for a while and only recently has started
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to be seriously investigated is the role of cytoplasmic PML iso-
forms and functions. Although aggregates of PML are visualized
mostly in the nucleus, we have known for a long time that a
number of PML splicing isoforms come into a cytoplasmic flavor
through exclusion of exon 6 (that contains a nuclear localization
signal) (10–19). Also PMLI, the most abundant isoform, is both
nuclear and cytoplasmic due to a nuclear export signal in its C-
terminus, and even in the nucleus it is probably most abundant in
the nucleoplasm rather that in the bright PML-NBs (19). To me,
the identification of novel functions of PML in the cytoplasm has
been among the most exciting recent advances of PML research.
Interestingly, similar to what we see in the nucleus, also in the
cytoplasm PML appears to be involved in a multitude of molecular
functions: it activates TGF-β signaling by promoting the associa-
tion of TGF-β receptors with SARA and Smad proteins at the early
endosome (20); it facilitates transfer of calcium to the mitochon-
dria and apoptosis by localizing at the mitochondria-associated
membranes of the endoplasmic reticulum (21); it interacts with
and suppresses the function of the M2 isoform of pyruvate kinase
(PKM2) thus suppressing tumor metabolism (22), even though
these findings are preliminary; and it regulates a number of
anti-viral responses (23).
Going back to the idea that different PML isoforms form dif-
ferent PML-NBs, one could imagine that function multiplicity
in the cytoplasm may also be explained by the presence of dif-
ferent cytoplasmic PML isoforms, although in the absence of a
more precise characterization of isoforms’ representation, this can
only be speculated at the moment. Alternatively, the specificity of
PML functions in the cytoplasm could be caused by its accumu-
lation into specific structures, such as endosomes or endoplasmic
reticulum, rather than by isoform specificity. In this respect, we
had observed that PML-induced stimulation of TGF-β signaling
could occur also upon expression of a truncated PML mutant
expressing only the N-terminal RBCC domain, and lacking any
C-terminal region in Pml null cells (20). In my view, a systematic
in vivo analysis in isoform-specific KO models is very much needed
and critically important; similarly important is the generation of
mouse mutant in which the PML-NBs could be visualized in their
in vivo dynamics. We are actively working on this.
Bernardi: With regard to the second point that you are making,
the idea that the regulation of PML functions may depend consid-
erably on its sub-cellular localization, this is further substantiated
by the notion that dynamic behaviors of PML have been described
also within the constraints of the cell nucleus. Indeed, I was quite
puzzled from the very first experiment that I conducted in your
lab, as I was studying the regulation of p53 by PML in conditions
of DNA damage, because I kept observing that upon specific DNA
damaging conditions, PML appeared to localize to an external
shell surrounding the nucleolus (24). Previous studies had already
described the localization of PML to the nucleolus upon inhibi-
tion of the proteasome (25). Interestingly, however, later studies
by the group of Hugues de Thé demonstrated that localization of
all PML isoforms to the nucleolus, or to aberrant nucleolar struc-
tures upon different kinds of cellular stress, is probably mediated
by PMLI, the most abundant PML isoform and the only one that
contains a nucleolar localization domain hidden in its C-terminus
(26). This takes us back to the issue of isoform specificity.
In any case, regardless of the specificity of PML isoforms, as
suggested by the group of Hugues de Thé, the functional inter-
play between PML and the nucleolus must be quite important
as it recurs in a number of circumstances in which PML plays
an important role, ranging from the response to DNA damage to
cell senescence. Also, the C-terminal region of PMLI, which con-
tains the nucleolar-targeting domain, is the most evolutionarily
conserved (26).
Pandolfi: It is well possible that the nucleolar localization of
PML might be crucial to exert some of its functions. Certainly
though, not all that PML does go through the nucleolus. And
more generally, what remains difficult to summarize for a general
audience is what exactly PML does in these various cellular sites,
and whether it exerts a specific enzymatic activity. The latter still
remains the key and most challenging question in the field.
From a historical perspective, research over the function of PML
has been greatly stimulated by the generation of Pml KO mice (5),
and the availability of primary cells lacking Pml expression. From
those early days on, through the work of many laboratories all
over the world, I think that the basic message that we have learnt
is that PML is a widely multifaceted protein that regulates many
important aspects of normal physiology and pathology. However,
PML functions are often subtle and unveiled only upon specific
experimental challenges. I still vividly remember the initial dis-
appointment when we discovered that Pml was dispensable for
embryonic life. I had moved to London to KO Pml in the mouse
after having read the seminal paper from Mario Capecchi and
colleagues describing the KO of the proto-oncogene int-2 [FGF3
(27)]. Those were early days, and the Pml KO mouse was one of
the first ever generated in Europe. After so much work to make the
Pml KO mouse, we were imagining the most severe of phenotypes,
and yet this was not the case: apparently the mice were fine. In ret-
rospect, though, we got our revenge in the years to follow. Since
then, many exiting functions of Pml were subsequently unraveled
by our group and others because of the Pml KO model.
Among the most important functions of PML, relevant to its
tumor suppressive activity is its ability to positively regulate the
function of p53 and family members, and negatively the PI3K
pathway, at multiple levels. The regulation of p53 by PML was one
of the first functions of PML to be dissected in molecular detail
(28–30), and over the years has been the most extensively validated:
literature over the cross-regulation of PML and p53 and its fam-
ily members has reached the two-digit figure, with approximately
20 independently published studies. The take home message is
that PML controls the expression and activity of p53 and family
members through multiple mechanisms, including facilitating a
number of post-translational modifications of p53 and interacting
with many factors that in turn regulate p53, p73, and p63 activity
(31–33). Recently, two independent papers confirmed that PML
and p53 also functionally interact in vivo, as loss of Pml contributes
significant alternations in tumor phenotypes in two mouse models
of p53-induced tumorigenesis (34, 35).
Bernardi: While I agree that this function of PML is the most
validated, I find exciting that new functions of PML are still emerg-
ing, and I think that these new aspects of PML biology will be
greatly investigated in the future. I am referring to the role of
PML in stem cell biology and metabolism, which also relates to
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regulating the PI3K pathway, as you mentioned. Indications that
PML regulates the biology of stem cells have come recently from
two elegant and unrelated studies in which the function of PML
was investigated in leukemia and hematopoietic stem cells (36),
and in neural stem cells (37). In the first paper, PML was described
as an essential regulator of stem cell maintenance, both in nor-
mal hematopoiesis and in chronic myeloid leukemia, as deletion
of Pml in KO mice led to loss of quiescence and exhaustion of
hematopoietic and leukemia stem cells (36). Interestingly, inhibi-
tion of Pml by arsenic trioxide disrupted maintenance of leukemia
initiating cells thus sensitizing leukemia to treatment with other
anti-leukemia agents (36). In the second paper, a thorough analy-
sis of the developing brain of Pml KO mice revealed that PML
suppresses proliferation and associates with the immature state of
neural progenitors by promoting cell cycle arrest (37).
As per the mechanisms involved in PML-regulated mainte-
nance of stem cell potential, an association of Pml loss with high
mTOR activity, in turn known to drive stem cell exhaustion, was
initially observed in hematopoietic stem cells (36). This obser-
vation further confirmed previous work where we had described
PML as a negative regulator of mTOR activity in hypoxic con-
ditions, thus leading to inhibition of hypoxia-inducible factors
signaling and tumor neo-angiogenesis (38). I think that this is
also very much coherent with the fact that the hematopoietic
stem cell niche is known to be a hypoxic environment. More
recently, however, it was also shown that in hematopoietic stem
cells PML stimulates fatty acid metabolism (39), which in turn
regulates stem cell maintenance and asymmetric stem cell division
at the expense of symmetric cell commitment (39). In the context
of neural stem cells, PML was implicated in a different mech-
anism of action, in line with its ability to maintain quiescence:
pRb-mediated regulation of cell cycle entry (37).
In summary, although a role for PML in regulating stem cell-
ness is emerging, mechanistically it is possible that PML regulates
stem cell maintenance through different mechanisms in differ-
ent tissues. In this respect, it should be mentioned that PML was
recently shown to also promote the expression of the stem cell
factor Oct4 in proliferating embryonic cells by regulating an open
chromatin state in its promoter (40).
Pandolfi: You rightly mention metabolism as the other emerg-
ing aspect of PML biology. The regulation of metabolism by PML
further complicates our simplistic perception of PML as a “good
guy”: the tumor suppressor for any stressful cellular condition.
Over the years, this notion had been very reassuring, and as you
know we are always reassured by simple models. However, PML,
which had been considered a tumor suppressor gene for over
20 years, is now found to exert oncogenic functions in specific
tumor contexts precisely because of its metabolic role. We came
to the understanding that PML might also behave as an oncogene
while we were further investigating its role in regulating metabo-
lism (39). We had already shown in several important studies that
PML regulates at multiple levels a very important proto-oncogenic
pathway, the PI3K/PTEN/AKT/mTOR signal transduction path-
way, which is also critical in metabolism and metabolic home-
ostasis. We had found that PML opposes this pathway at multiple
levels: by favoring PTEN proper nuclear cytosolic shuttling though
its ability to oppose HAUSP deubiquitilation (41); by inactivating
nuclear Akt through dephosphorylation into the PML-NBs (42),
and by regulating nuclear accumulation and activity of mTOR in
conditions of hypoxia, thus impinging onto hypoxia-responsive
pathways (38).
More recently, however, we found that PML exerts another
important metabolic function by acting as a potent activator of
PPAR signaling and positively regulating fatty acid oxidation (39).
While this function of PML supports asymmetric cell division in
normal hematopoietic stem cells (39), it also inhibits cell death
by anoikis hence favoring cell survival in breast cancer cells (39).
Therefore, together with our previous identification of PML as
a protective agents against leukemia stem cell exhaustion (36),
these new data reinforce the concept that in specific cell contexts
PML may also play oncogenic functions besides its best-known
tumor suppressive activities. Implications of these new data have
been recently discussed in two dedicated reviews (43, 44). Inter-
estingly, another study indicates that in Pml KO tissues a variety
of metabolic pathways are tissue-specifically de-regulated with
respect to wt animals, such as for instance glucose metabolism
and AMPK activation, thus suggesting that the role of PML in
regulating metabolism may go beyond the regulation of fatty acid
oxidation (45).
Bernardi: Certainly, the idea that PML has pro-oncogenic
functions in specific contexts is intriguing. Dual activities are
not unprecedented for oncogenes and tumor suppressors alike,
and it is plausible that different outcomes of PML expression
may be dictated by cell specific contexts. Indeed, although many
studies have documented loss of expression of PML in tumors
of different histological origin, more recently high expression
of PML has been reported in triple-negative breast cancer and
chronic myeloid leukemia (36, 39). A future challenge will be
to understand what are the discriminating genetic co-factors
of PML oncogenic or tumor suppressive functions and which
other, if any, tumor type might benefit of PML tumor-promoting
functions.
In closing, tell me three aspects that excite you the most
regarding PML research in the next 20 years.
Pandolfi: I would say: (i) PML regulation and function; (ii)
PML enzymatic activity; and (iii) implication for therapy, and not
necessarily in order of importance. Regarding PML regulation, we
have mentioned PML isoforms, but I think that there is a lot to be
learned by studying the mechanisms or post-transcriptional reg-
ulation of PML, and undoubtedly, additional functions of PML
will be uncovered in the future. Importantly, I think that we are
still scratching our heads concerning whether or not PML exerts a
distinct enzymatic activity. While I am excited by the essential role
that PML plays in the formation of the PML-NBs (11), I still hope
that there’s an enzymatic function of PML that we have failed to
discover thus far. A possible PML enzymatic activity, if any, will
prove extremely instructive of PML research in the years to come.
Lastly, I hope that collectively we will find pharmacological ways
to modulate PML therapeutically for the treatment of cancer and
other disorders. This proved already critical to the eradication of
APL. We should never forget that one of the main reasons why
arsenic trioxide has led to APL cure is because it can target PML-
RAR and also PML for degradation (39, 46). I therefore think
that in the years to come PML research will pave the way to new
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discoveries and therapies for cancer and other diseases. So, we will
keep actively working on PML and you Rosa should do the same
in your lab!
Bernardi: I sure will.
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